The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Biomarkers to Support Therapeutic Trials Program, 2023Using Neurophysiology as a Stratification Tool for Synucleinopathy
Study Rationale: Although numerous disease-modifying drugs are being developed for Parkinson’s disease (PD), the current methods used to identify people suitable for clinical trials are costly...
-
Research Grant, 2022Extending Assessment of WATCH-PD Remote Digital Technology
Study Rationale: Digital tools can provide objective, sensitive, real-world measures of Parkinson’s disease (PD). Better measures could lead to more efficient, patient-centric and timely evaluation of...
-
Translational Pipeline Program, 2022Investigating GPR55 as a Novel Neuroprotective Target in Preclinical Models of Parkinson’s Disease
Study Rationale: Cannabinoids — substances derived from the cannabis plant — have demonstrated neuroprotective properties useful for the treatment of neurodegenerative disorders. Although these...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Effects of Chemical Modifications on Aggregation of Alpha-synuclein
Study Rationale: Evidence suggests that alpha-synuclein causes the death of neurons in the brains of people with Parkinson’s disease (PD) by forming clusters (or ‘aggregates’) on the surface of...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Targeting the Dopamine D1 Receptor for a Treatment of Parkinson’s Disease with Minimal L-DOPA-induced Dyskinesia
Study Rationale: L-DOPA is the primary drug used for treating the mobility loss that occurs in Parkinson’s disease (PD) due to decreases in dopamine. Although L-DOPA enhances mobility, chronic...
-
Translational Pipeline Program, 2023Evaluation of Glunomab, a Novel Immunotherapy for the Treatment of Parkinson’s Disease
Study Rationale: Glunomab is a monoclonal antibody that inhibits a toxic interaction between two proteins recently determined to be involved in the pathology of Parkinson’s disease (PD). Because its...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.